Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Common Equity: 2023-2025

Historic Common Equity for Artiva Biotherapeutics (ARTV) over the last 3 years, with Sep 2025 value amounting to $129.2 million.

  • Artiva Biotherapeutics' Common Equity fell 35.71% to $129.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.2 million, marking a year-over-year decrease of 35.71%. This contributed to the annual value of $186.6 million for FY2024, which is 215.20% up from last year.
  • As of Q3 2025, Artiva Biotherapeutics' Common Equity stood at $129.2 million, which was down 13.30% from $149.0 million recorded in Q2 2025.
  • In the past 5 years, Artiva Biotherapeutics' Common Equity ranged from a high of $201.0 million in Q3 2024 and a low of -$191.1 million during Q2 2024.
  • For the 3-year period, Artiva Biotherapeutics' Common Equity averaged around -$880,900, with its median value being -$11.1 million (2023).
  • As far as peak fluctuations go, Artiva Biotherapeutics' Common Equity spiked by 232.71% in 2024, and later tumbled by 35.71% in 2025.
  • Over the past 3 years, Artiva Biotherapeutics' Common Equity (Quarterly) stood at -$162.0 million in 2023, then spiked by 215.20% to $186.6 million in 2024, then plummeted by 35.71% to $129.2 million in 2025.
  • Its Common Equity stands at $129.2 million for Q3 2025, versus $149.0 million for Q2 2025 and $168.8 million for Q1 2025.